Indaptus Therapeutics (INDP) EPS (Basic) Growth (3y) (2023 - 2026)
Indaptus Therapeutics (INDP) EPS (Basic) Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | -38.31% |
| 10 | Indaptus Therapeutics | 145.16 Mn | 133.61 Mn | - | 88.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.04% |
| Mar 31, 2026 | 75.77% |
| Dec 31, 2025 | 14.01% |
| Sep 30, 2025 | 39.25% |
| Jun 30, 2025 | 12.45% |
| Mar 31, 2025 | 8.44% |
| Dec 31, 2024 | 17.27% |
| Sep 30, 2024 | 31.20% |
| Jun 30, 2024 | 95.46% |
| Mar 31, 2024 | 94.89% |
| Dec 31, 2023 | -6.91% |
| Sep 30, 2023 | 10.44% |
| Jun 30, 2023 | 95.09% |
| Mar 31, 2023 | 95.74% |